Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286102 | 0.88 | ACHE (0.42) | ACHENOS3NOS1NOS2 | |
| SCHEMBL29532721 | 0.78 | HTR2A (0.39) | EPAS1ACHE | |
| SCHEMBL1424574 | 0.78 | HTR2A (0.39) | EPAS1ACHE | |
| SCHEMBL8263257 | 0.78 | HTR2A (0.39) | EPAS1 | |
| SCHEMBL379328 | 0.78 | HTR2A (0.39) | EPAS1ACHE | |
| SCHEMBL15267245 | 0.78 | HTR2A (0.39) | EPAS1ACHE | |
| SCHEMBL13270953 | 0.78 | HTR2A (0.39) | EPAS1ACHENOS3NOS2 | |
| SCHEMBL17144461 | 0.74 | ADRA1A (0.40) | EPAS1 | |
| SCHEMBL18629742 | 0.74 | EPAS1 (0.35) | EPAS1 | |
| SCHEMBL8054157 | 0.73 | USP2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185541-B1 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | disclosed |
| US-8853406-B2 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | Janssen Pharmaceutica NV a corporation | 2011-12-01 | — | — | US | disclosed |
| US-20110130418-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN-CILAG (FR) | 2011-06-02 | — | — | US | disclosed |
| WO-2010089327-A2 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009019274-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130418-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | EPAS1 1106/4885ACHE 1808/4885NOS3 3053/4885 |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | IDO1, IDO2, INMT | EPAS1 2204/4885ACHE 2626/4885NOS3 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.